

PRINTER RUSH
(PTO ASSISTANCE)

Application : 10634682 Examiner : Balasubramanian GAO : 1624
From : J. Black Location : IDC FMF FDC Date : 3/27/06
Tracking # : epm10634682 Week Date : 8/15/05

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449		<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS		<input type="checkbox"/> Foreign Priority
<input checked="" type="checkbox"/> CLM	<u>8/10/05</u>	<input type="checkbox"/> Document Legibility
<input checked="" type="checkbox"/> IIFW		<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW		<input type="checkbox"/> Other
<input type="checkbox"/> DRW		
<input type="checkbox"/> OATH		
<input type="checkbox"/> 312		
<input type="checkbox"/> SPEC		

[RUSH] MESSAGE:

Claim 28 depends on claim 29.

Please resolve.

[XRUSH] RESPONSE:

Done

INITIALS [Signature]

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.

REV 10/04


Appln. No. 10/634,682

24. (New) A pyrimidinyl compound as claimed in claim 23, wherein the compound is the hydrochloride salt of 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile.

25. (New) A pyrimidinyl compound as claimed in claim 1, wherein the compound is a quaternary amine of 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile.

26. (New) A pharmaceutical composition as claimed in claim 3, wherein the pharmaceutical composition is a tablet.

27. (New) A pharmaceutical composition as claimed in claim 3, wherein the effective amount is between 1 to 1000 mg of active ingredient per unit dosage form.

 28. (New) A pharmaceutical composition as claimed in claim 29, wherein the effective amount is between 5 and 200 mg of active ingredient per unit dosage form.

29. (New) A tablet as claimed in claim 26, wherein the effective amount is between 1 to 1000 mg of active ingredient.

30. (New) A tablet as claimed in claim 29, wherein the effective amount is between 5 to 200 mg of active ingredient.

31. (New) A method of treating subjects suffering from HIV-1 (Human Immunodeficiency Virus) infection that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors comprising administering to the subject an effective amount of a compound according to any of claims 1 or 2.

32. (New) A method of treating subjects suffering from HIV-1 (Human Immunodeficiency Virus) infection that have acquired resistance to art-known non-nucleoside reverse transcriptase inhibitors comprising administering to the subject an effective amount of a combination comprising a pyrimidinyl compound according to any of claims 1 or 2 and an